Saisei Mirai 2nd Generation High Dose GcMAF macrophage activity assays and tests

Therapy | Treatment

GcMAF (Gc Protein derived
Macrophage Activating Factor)

For the treatment for cancer, HIV and immune system diseases.

Tests of Second Generation GcMAF

Experiment report
14-JUN-2012 Stability of GcMAF in Serum (PDF)
H Mukai, Y Uto. Department of Biological Science and Technology, The University of Tokushima.
  • This experiment was conducted at the University of Tokushima in Japan, using our 2nd generation GcMAF demonstrating macrophage phagocytic activity after short-term and long-term storage conditions. The results show that 2nd generation GcMAF in serum is stable for 1 year at 4 °C, for 14 days at room temperature (around 20 °C), and for 7 days at 40 °C.
  • Please note, this research only applies to second generation GcMAF produced with our Patent Pending production process. GcMAF produced using the old method, using vitamin D affinity chromatography, does not have the same stability as 2nd generation GcMAF because it is susceptible to much more rapid oxidation. This difference in stability is due to the different production process, not due to the GcMAF itself.

Macrophage phagocytic activity assay of Second Generation GcMAF

Macrophage phagocytic activity assay using mouse macrophages

Second generation GcMAF is tested for macrophage phagocytic activity using mouse macrophages and sheep red blood cells at the University of Tokushima. The red blood cells are opsonized which marks them for ingestion and destruction by activated macrophages, seen as purple areas in the clear cells. From this we calculate the Phagocytosis (ingestion) Index (PI).


Macrophage phagocytic activity assay of second generation GcMAF
The purple color are macrophages activated by GcMAF phagocytizing (ingesting) opsonized red blood cells which are clear in color. Photo courtesy, University of Tokushima.
Macrophage phagocytic activity assay of second generation GcMAF
Phagocytosis assay with Second Generation GcMAF. Photo courtesy, University of Tokushima.

Macrophage phagocytic activity assay using macrophage cell line THP-1 and fluorescent beads

Macrophage cell line THP-1 incubated (A) without GcMAF and (B) with Second Generation GcMAF (500 ng/ml GcMAF for 120 min) after addition of fluorescent beads (red), which started to glow red fluorescence after engulfment. Although red fluorescent beads were found within macrophages in both treatment groups A and B (indicated by white arrow), a much larger number of florescent bead were stacked beside the nucleus (blue) in the GcMAF treatment group. This result shows that Second Generation GcMAF strongly activates macrophages and enhances the engulfment of beads used in this assay system. THP-1 cell line macrophages were induced by 10ng/ml 12-O-Tetradecanoylphorbol-13-acetate (TPA).


Macrophage phagocytic activity assay using fluorescent beads
Micropscope picture showing macrophage phagocytic activity assay using macrophage cell line THP-1 and fluorescent beads. (A) Macrophages not activated by GcMAF show little phagocytic activity. (B) Macrophages activated by Second Generation GcMAF show very high phagocytic activity seen by the much larger number of red florescent beads engulfed by the macrophages. Photo courtesy, Frontier Institute for Biomolecular Engineering Research (FIBER), Konan University, Kobe, Japan.

Research paper
For more on this assay system, see A Novel Assay System for Macrophage-activating Factor Activity Using a Human U937 Cell Line
Anticancer Research 34: 4577-4581, 2014.

Increased rate of maturation of Dendritic cells (DCs) in vitro

In vitro experiments conducted by Saisei Mirai indicate increased rate of maturation of dendritic cells (DCs), a type of immune cell, with 2nd Generation GcMAF. This graph shows specific marker expression of dendritic cells grown from normal peripheral blood with and without 2nd Generation GcMAF after 6 and 8 days cultivation. From this preliminary experiment we observed that 2nd Generation GcMAF increases the rate of maturation of dendritic cells.

The ability of dendritic cells to regulate immunity is dependent on DC maturation. The process of DC maturation, results in an increase in the surface expression of costimulatory molecules, morphological changes (such as formation of dendrites), secretion of chemokines, cytokines and proteases, and surface expression of adhesion molecules and chemokine receptors.


Increased rate of maturation of dendritic cells (DCs) with GcMAF
Flow cytometric analysis of dendric cells (DCs) grown from normal peripheral blood with and without 2nd Generation GcMAF on specific marker expression after 6 and 8 days cultivation.

How does this test work?

Mature DCs are detected by the presence or absence of various molecules on their cell surface. These include molecules such as CD83+, HLA-DR+, CD86+, CD1a, CD11c which can be measured.


Helix pomatia agglutinin (HPA) lectin (for GalNAc residue)

Second generation Gc-MAF is identified using electrophoresis Western blot with Helix pomatia agglutinin (HPA) lectin (for GalNAc residue).

Identification of Gc-MAF with Helix pomatia agglutinin lectin
Photo courtesy, University of Tokushima.

Oral Colostrum GcMAF macrophage activity assay

We find that 100 ng Oral Colostrum MAF has equivalent macrophage phagocytic activity to 10 ng first generation GcMAF. Pure colostrum has no significant activity compared to control, so pure colostrum does not activate macrophages unless modified using our patented technology.

Oral Colostrum MAF (macrophage activating factor) is administered orally in the gut in an Enteric capsules and as a powder in the mouth by opening the capsule. This activates macrophages in the lymphoid tissue of the gut and mouth which are important parts of our immune system.


Oral Colostrum GcMAF macrophage phagocytic activity assay
Oral Colostrum GcMAF macrophage phagocytic activity (orange bars) in comparison to first generation GcMAF (green bar) and unmodified pure colostrum (white bars).

If you wish to purchase GcMAF therapy or make an enquiry, please contact us with details of your disease, current treatment and the quantities of Gc-MAF you require.



News

Heart Pharmacy website gcmaf.co.jp is now open

Purchase your Colostrum MAF here using PayPal or credit card.

→ Heart Pharmacy website


2016 Integrative Medical Therapies Conference - Osaka, Japan

Thank you very much for your participation at the Saisei Mirai 2016 Integrative Medical Therapies conference in Osaka, held on Sunday 13th November 2016.

→ 2016 Integrative Medical Therapies conference - Osaka, Japan


Genostics Conference - Sydney, Australia

24-SEP-2016
Dr Toshio Inui

→ Genostics official website


Symposium on Integrated Medicine: Electric Fields Therapy & Immunotherapy - Jakarta, Indonesia


22-JUL-2016
Dr. Toshio Inui gave a presentation of the electric field therapy and second-generation GcMAF and colostrum MAF at a conference which was held in Jakarta, Indonesia on July 22, 2016.



International Pharmacy Conference

14 to 15-JUL-2016
Dr. Shinichiro Akiyama at International Pharmacy Conference, which was held in the United States Philadelphia, Pennsylvania on July 14 to 15, 2016, the Clinical experience of colostrum derived protein against solid cancer has been announced as the Keynote Speaker.



New New research papers published by Saisei Mirai in Anticancer Research available online.

Research paper
2016 Case Report: GcMAF Treatment in a Patient with Multiple Sclerosis (PDF)
ANTICANCER RESEARCH 36: 3771-3774 (2016)

Case Report: GcMAF Treatment in a Patient with Multiple Sclerosis Case Report: GcMAF Treatment in a Patient with Multiple Sclerosis Case Report: GcMAF Treatment in a Patient with Multiple Sclerosis

Research paper
2016 Case Report: A Non-small Cell Lung Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Tumor Treating Fields (PDF)
ANTICANCER RESEARCH 36: 3767-3770 (2016)

Case Report: A Non-small Cell Lung Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Tumor Treating Fields Case Report: A Non-small Cell Lung Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Tumor Treating Fields Case Report: A Non-small Cell Lung Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Tumor Treating Fields

Research paper
2016 Macrophages Exhibit a Large Repertoire of Activation States via Multiple Mechanisms of Macrophage-activating Factors (PDF)
ANTICANCER RESEARCH 36: 3619-3624 (2016)

Macrophages Exhibit a Large Repertoire of Activation States via Multiple Mechanisms of Macrophage-activating Factors Macrophages Exhibit a Large Repertoire of Activation States via Multiple Mechanisms of Macrophage-activating Factors Macrophages Exhibit a Large Repertoire of Activation States via Multiple Mechanisms of Macrophage-activating Factors

New research papers published by Saisei Mirai in Anticancer Research available online.

New research papers on Oral Colostrum GcMAF for Chronic Fatigue Syndrome (CFS) and serious infection published in Anticancer Research journal.

Research paper
2015 Oral Colostrum Macrophage-activating Factor for Serious Infection and Chronic Fatigue Syndrome: Three Case Reports (PDF)
Anticancer Res August 2015 35 (8) 4545-4549

Conference presentation - 10th International Congress for Medical Laser Applications, Germany

13-JUN-2015
Clinical application of Second Generation GcMAF and oral GcMAF
Dr Toshio Inui

Clinical application of Second Generation GcMAF and oral GcMAF
ISLA website

Conference presentation - 9th International Congress for Medical Laser Applications, Germany

29-JUN-2014
Indications for GcMAF for immunotherapy of cancers and chronic viral and bacterial infections (PDF)

Dr Toshio Inui

Dr Toshio Inui Indications for GcMAF for immunotherapy of cancers and chronic viral and bacterial infections

Conference presentation - The 17th Annual Meeting of The Society of Biotherapeutic Approaches, Fukuoka University

7-DEC-2013
Case Report: A Breast Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Hormone Therapy (PDF), PPT

Dr Toshio Inui

Dr Toshio Inui Case Report - A Breast Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Hormone Therapy

New research papers published by Saisei Mirai in Anticancer Research available online.

New research papers on GcMAF and integrative cancer immunotherapy treatment written in collaboration with the University of Tokushima, Kanazawa University and Kobe University Graduate School of Medicine researchers and Saisei Mirai published in Anticancer Research journal.

Research paper
2013 Degalactosylated/Desialylated Human Serum Containing GcMAF Induces Macrophage Phagocytic Activity and In Vivo Antitumor Activity (PDF)
Anticancer Res July 2013 33 (7) 2881-2885

Cancer vaccine therapy - autologous tissue derived tumor vaccine Cancer vaccine therapy - autologous tissue derived tumor vaccine Cancer vaccine therapy - autologous tissue derived tumor vaccine

Research paper
2013 Clinical Experience of Integrative Cancer Immunotherapy with GcMAF (PDF)
Anticancer Res July 2013 33 (7) 2917-2919

Cancer vaccine therapy - autologous tissue derived tumor vaccine Cancer vaccine therapy - autologous tissue derived tumor vaccine Cancer vaccine therapy - autologous tissue derived tumor vaccine

Nature Outlook sponsored article

For more details on GcMAF see our GcMAF page.



Experiment report of Gc MAF stability assay
14-JUN-2012 Stability of GcMAF in Serum (PDF)
H Mukai, Y Uto. Department of Biological Science and Technology, The University of Tokushima.

Stability of GcMAF in Serum report Stability of GcMAF in Serum report

The results show that 2nd Generation GcMAF is stable for 1 year at 4 °C, for 14 days at room temperature (around 20 °C), and for 7 days at 40 °C.

See Research and references for more details on experiments on macrophage phagocytic activity and stability of our GcMAF.


Collaborations with the University of Tokushima
We collaborate with GcMAF researchers at the University of Tokushima, Japan in the development of second generation GcMAF. See Research and references for published research papers on Gc-MAF in peer-reviewed scientific journals authored by the University of Tokushima researchers over the last decade. Our research on GcMAF is ongoing and papers are being prepared for publication in collaboration between the University of Tokushima and Saisei Mirai in the next few months.


University of Tokushima, Institute of Technology and Science, Laboratory Research

Our research group:


Imagin-K

Contact us
GcMAF
Treatments and therapies
Contact us

Saisei Mirai Clinics
Kobe Saisei Mirai Clinic
  • Cancer
  • Skin regeneration
  • Skin rejuvenation
  • Anti-aging
Kobe Saisei Mirai Clinic

Boeki Center Building
23rd Floor
5-1-14 Hamabetori Chuo-ku
Kobe-shi
Hyogo-ken 651-0083
Japan


Inui Cancer
Immunotherapy Clinic
  • Cancer
  • Hepatitis
  • Chronic diseases
Inui Cancer Immunotherapy Clinic

6-14-17 Kindachou
Moriguchi-shi
Osaka 570-0011
Japan
TEL: +81 (0)6-6902-5251
FAX: +81 (0)6-6902-7133

Inui Cancer Immunotherapy Clinic

Keihan Clinic
  • Cancer
  • Hepatitis
  • Chronic diseases
  • Anti-aging
Saisei Mirai Keihan Clinic

Nature 21 Building
2nd Floor
3-34-8 Okubo-cho
Moriguchi-shi
Osaka 570-0012
Japan
TEL: +81 (0)6-6902-1001


R Future Cancer Int'l Clinic
  • Cancer
R Future Cancer Int'l Clinic

ORE Hiroo Building
7th Floor
5-10-26 Minamiazabu
Minato-ku
Tokyo-to 106-0047
Japan


R Science Clinic
  • Skin regeneration
  • Skin rejuvenation
  • Anti-aging
R Mirai Clinic

ORE Hiroo Building
6th Floor
5-10-26 Minamiazabu
Minato-ku
Tokyo-to 106-0047
Japan


Immunotherapy Lab
  • Cell Processing Center
Immunotherapy Lab

Nature 21 Building
3rd Floor
3-34-8 Okubo-cho
Moriguchi-shi
Osaka 570-0012
Japan